198 related articles for article (PubMed ID: 9417048)
1. Specificity of mouse GM2 activator protein and beta-N-acetylhexosaminidases A and B. Similarities and differences with their human counterparts in the catabolism of GM2.
Yuziuk JA; Bertoni C; Beccari T; Orlacchio A; Wu YY; Li SC; Li YT
J Biol Chem; 1998 Jan; 273(1):66-72. PubMed ID: 9417048
[TBL] [Abstract][Full Text] [Related]
2. The human GM2 activator protein. A substrate specific cofactor of beta-hexosaminidase A.
Meier EM; Schwarzmann G; Fürst W; Sandhoff K
J Biol Chem; 1991 Jan; 266(3):1879-87. PubMed ID: 1824846
[TBL] [Abstract][Full Text] [Related]
3. In cellulo examination of a beta-alpha hybrid construct of beta-hexosaminidase A subunits, reported to interact with the GM2 activator protein and hydrolyze GM2 ganglioside.
Sinici I; Yonekawa S; Tkachyova I; Gray SJ; Samulski RJ; Wakarchuk W; Mark BL; Mahuran DJ
PLoS One; 2013; 8(3):e57908. PubMed ID: 23483939
[TBL] [Abstract][Full Text] [Related]
4. Formation of a ternary complex between GM2 activator protein, GM2 ganglioside and hexosaminidase A.
Yadao F; Hechtman P; Kaplan F
Biochim Biophys Acta; 1997 Jun; 1340(1):45-52. PubMed ID: 9217013
[TBL] [Abstract][Full Text] [Related]
5. Catabolism of asialo-GM2 in man and mouse. Specificity of human/mouse chimeric GM2 activator proteins.
Bertoni C; Li YT; Li SC
J Biol Chem; 1999 Oct; 274(40):28612-8. PubMed ID: 10497228
[TBL] [Abstract][Full Text] [Related]
6. Inefficiency in GM2 ganglioside elimination by human lysosomal beta-hexosaminidase beta-subunit gene transfer to fibroblastic cell line derived from Sandhoff disease model mice.
Itakura T; Kuroki A; Ishibashi Y; Tsuji D; Kawashita E; Higashine Y; Sakuraba H; Yamanaka S; Itoh K
Biol Pharm Bull; 2006 Aug; 29(8):1564-9. PubMed ID: 16880605
[TBL] [Abstract][Full Text] [Related]
7. The specificity of human N-acetyl-beta-D-hexosaminidases towards glycosphincolipids is determined by an activator protein.
Conzelmann E; Sandhoff K
Adv Exp Med Biol; 1980; 125():295-306. PubMed ID: 6444774
[TBL] [Abstract][Full Text] [Related]
8. A single site in human beta-hexosaminidase A binds both 6-sulfate-groups on hexosamines and the sialic acid moiety of GM2 ganglioside.
Sharma R; Bukovac S; Callahan J; Mahuran D
Biochim Biophys Acta; 2003 Jan; 1637(1):113-8. PubMed ID: 12527415
[TBL] [Abstract][Full Text] [Related]
9. A Pro504 --> Ser substitution in the beta-subunit of beta-hexosaminidase A inhibits alpha-subunit hydrolysis of GM2 ganglioside, resulting in chronic Sandhoff disease.
Hou Y; McInnes B; Hinek A; Karpati G; Mahuran D
J Biol Chem; 1998 Aug; 273(33):21386-92. PubMed ID: 9694901
[TBL] [Abstract][Full Text] [Related]
10. Direct determination of the substrate specificity of the alpha-active site in heterodimeric beta-hexosaminidase A.
Hou Y; Tse R; Mahuran DJ
Biochemistry; 1996 Apr; 35(13):3963-9. PubMed ID: 8672428
[TBL] [Abstract][Full Text] [Related]
11. Expression and specificity of human GM2 activator protein.
Wu YY; Lockyer JM; Sugiyama E; Pavlova NV; Li YT; Li SC
J Biol Chem; 1994 Jun; 269(23):16276-83. PubMed ID: 8206933
[TBL] [Abstract][Full Text] [Related]
12. Juvenile GM2 gangliosidosis (AMB variant): inability to activate hexosaminidase A by activator protein.
Inui K; Grebner EE; Jackson LG; Wenger DA
Am J Hum Genet; 1983 Jul; 35(4):551-64. PubMed ID: 6224417
[TBL] [Abstract][Full Text] [Related]
13. Physiological substrates for human lysosomal beta -hexosaminidase S.
Hepbildikler ST; Sandhoff R; Kolzer M; Proia RL; Sandhoff K
J Biol Chem; 2002 Jan; 277(4):2562-72. PubMed ID: 11707436
[TBL] [Abstract][Full Text] [Related]
14. Mouse model of GM2 activator deficiency manifests cerebellar pathology and motor impairment.
Liu Y; Hoffmann A; Grinberg A; Westphal H; McDonald MP; Miller KM; Crawley JN; Sandhoff K; Suzuki K; Proia RL
Proc Natl Acad Sci U S A; 1997 Jul; 94(15):8138-43. PubMed ID: 9223328
[TBL] [Abstract][Full Text] [Related]
15. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases.
Huang JQ; Trasler JM; Igdoura S; Michaud J; Hanal N; Gravel RA
Hum Mol Genet; 1997 Oct; 6(11):1879-85. PubMed ID: 9302266
[TBL] [Abstract][Full Text] [Related]
16. Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases.
Phaneuf D; Wakamatsu N; Huang JQ; Borowski A; Peterson AC; Fortunato SR; Ritter G; Igdoura SA; Morales CR; Benoit G; Akerman BR; Leclerc D; Hanai N; Marth JD; Trasler JM; Gravel RA
Hum Mol Genet; 1996 Jan; 5(1):1-14. PubMed ID: 8789434
[TBL] [Abstract][Full Text] [Related]
17. Isolation and characterization of an activator protein for the hydrolysis of ganglioside GM2 from the roe of striped mullet (Mugil cephalus).
DeGasperi R; Li YT; Li SC
Biochem J; 1989 Jun; 260(3):777-83. PubMed ID: 2527497
[TBL] [Abstract][Full Text] [Related]
18. Lyso-GM2 ganglioside: a possible biomarker of Tay-Sachs disease and Sandhoff disease.
Kodama T; Togawa T; Tsukimura T; Kawashima I; Matsuoka K; Kitakaze K; Tsuji D; Itoh K; Ishida Y; Suzuki M; Suzuki T; Sakuraba H
PLoS One; 2011; 6(12):e29074. PubMed ID: 22205997
[TBL] [Abstract][Full Text] [Related]
19. [Isolation and characteristics of hexosaminidase A and activator protein from human kidney].
Aronovich EL; Akhunov VS; Krasnopol'skaia KD
Biokhimiia; 1990 Jan; 55(1):43-51. PubMed ID: 2140519
[TBL] [Abstract][Full Text] [Related]
20. Crystallographic structure of human beta-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis.
Lemieux MJ; Mark BL; Cherney MM; Withers SG; Mahuran DJ; James MN
J Mol Biol; 2006 Jun; 359(4):913-29. PubMed ID: 16698036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
